All In Biotech

BLA 761325 · Sanofi-Aventis U.S. LLC

Merilog

Insulin Aspart-Szjj · Solution · Insulin Analog

Last checked: Nov 20, 2026Latest source record: Feb 14, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Feb 14, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

485

129 Phase 3, 9 recruiting

FAERS reports

10

2 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 7, 2025.

MERILOG is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. MERILOG is rapid acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus ( 1 ).

Mechanism: The primary activity of insulin, including insulin aspart products is the regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • MERILOG · INSULIN ASPART-SZJJ 10ML(100UNITS/ML) · INJECTION, SOLUTION · Prescription
  • MERILOG SOLOSTAR · INSULIN ASPART-SZJJ 3ML(100UNITS/ML) · INJECTION, SOLUTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Insulin Aspart" as an intervention, any sponsor and status, largest first.

All 485 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective2
  • off label use2
  • blood glucose abnormal1
  • blood glucose increased1
  • hyperhidrosis1
  • hyperthyroidism1
  • hypoglycaemia1
  • hypoglycaemic coma1
  • incorrect route of product administration1
  • intentional overdose1
  • intentional product misuse1
  • loss of consciousness1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20252
20268

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 481 on PubMed

Sponsor: Sanofi · Also marketed as Merilog Solostar

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.